Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin with BFM Re-Induction for R/R B-ALL
NCT03962465Phase 1Active, not recruiting
- Sponsor
- University of Virginia
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL) (2 arms), sponsored by University of Virginia. Primary endpoints: Characterization of Adverse Events (CTCAE version 5), Dose-limiting toxicities and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT03962465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962465.